within Pharmacolibrary.Drugs.ATC.L;

model L01BC02_1
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0007166666666666666,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.014,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.012,
    k12             = 40,
    k21             = 40
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01BC02_1</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Fluorouracil (5-FU) is an antimetabolite chemotherapy drug for cancers such as colorectal and breast cancer, disrupting DNA synthesis by inhibiting thymidylate synthase. Approved and commonly used intravenously.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in adults receiving continuous IV infusion.</p><h4>References</h4><ol><li><p>Diasio, RB, &amp; Harris, BE (1989). Clinical pharmacology of 5-fluorouracil. <i>Clinical pharmacokinetics</i> 16(4) 215–237. DOI:<a href=&quot;https://doi.org/10.2165/00003088-198916040-00002&quot;>10.2165/00003088-198916040-00002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2656050/&quot;>https://pubmed.ncbi.nlm.nih.gov/2656050</a></p></li><li><p>Ismael, G, et al., &amp; Jackisch, C (2012). Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. <i>The Lancet. Oncology</i> 13(9) 869–878. DOI:<a href=&quot;https://doi.org/10.1016/S1470-2045(12)70329-7&quot;>10.1016/S1470-2045(12)70329-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22884505/&quot;>https://pubmed.ncbi.nlm.nih.gov/22884505</a></p></li><li><p>De Bruijn, EA, et al., &amp; Tjaden, UR (1988). Pharmacokinetics of intravenous and oral cyclophosphamide in the presence of methotrexate and fluorouracil. <i>Pharmaceutisch weekblad. Scientific edition</i> 10(5) 200–206. DOI:<a href=&quot;https://doi.org/10.1007/BF01956871&quot;>10.1007/BF01956871</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3205676/&quot;>https://pubmed.ncbi.nlm.nih.gov/3205676</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01BC02_1;
